The development of inhibitory antibodies directed against human factor Vlll (h-fVIII) remains the most signiflcant clinical complication associated with the treatment of hemophilia A and is a critical barrier to gene therapy approaches. Not dissimilar to what occurs in the majority of monogenic diseases treated using protein replacement therapy, 20 - 30% of hemophilia A patients develop an immune response to the infused fVIII product that renders treatment ineffective. Therefore, the discovery and development of new methods to induce immune tolerance or hypo-responsiveness are needed. Hematopoietic stem cell transplantation (HSCT) protocols are showing promise in clinical trials for the treatment of a variety of human autoimmune disorders. Furthermore, HSCT combined with gene therapy has been shown, at least in animal models, to facilitate the introduction of and tolerance to neo or allo-antigens, such as those proteins deficient in monogenic diseases like hemophilia A. Our laboratories recently reported that transplantation of geneticallymodified HSCs containing a high-expression porcine (p)-fVIII transgene into hemophilia A mice results in the production of high levels of circulating fVlll activity. None of the recipient mice developed anti-fVlll antibodies following HSCT gene therapy, even in the context of non-myeloablative and non-radiation-based conditioning. Subsequently, we studied HSCT gene therapy in hemophilia A mice harboring anfi-hfVlll inhibitory antibody titers. Even though the majority of mice contained circulating antibodies that cross-reacted with and inhibited p-fVIII activity in vitro, transplantation of genetically-modified HSCs expressing p-fVlll into myeloablated hemophilia A mice restored circulating fVIII activity. Curative p-fVlll activity levels persisted and anti-h-fVIII antibody titers steadily declined throughout the course of the study in all mice. In contrast, the use of non-myeloablative total body irradiation (TBI) was only partially successful in promoting the engraftment of genetically-modified cells and resulted in a delayed reduction of anti-fVIII antibody titers. Therefore, pre-existing immunity presents an additional barrier to HSCT gene therapy. These data suggest that, while HSCT-based gene therapy incorporating a p-fVIII can be utilized successfully for the treatment of patients with refractory anti-hfVIII inhibitors, 1) more aggressive transplant conditioning is necessary to achieve disease correction, 2) the use of an orthologous (or other non-idenfical antigen) transgene product is critical, and 3) enduring tolerance/hyporesponsiveness can be achieved. The focus of this proposal is to develop an HSCT gene therapy strategy for the treatment of hemophilia A when complicated by inhibitors.

Public Health Relevance

Gene therapy offers the potential for long-term impact on the health of patients with hemophilia A. However, the immune response to fVIII remains a significant obstacle, and existing immunity represents a formidable challenge to the development of gene therapy treatments for hemophilia. The goal of this proposal is to develop a gene therapy treatment that can be applied to patients with fVlll inhibitors.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54HL112309-03
Application #
8656795
Study Section
Special Emphasis Panel (ZHL1)
Project Start
Project End
Budget Start
2014-05-01
Budget End
2015-04-30
Support Year
3
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Emory University
Department
Type
DUNS #
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Batsuli, Glaivy; Deng, Wei; Healey, John F et al. (2016) High-affinity, non-inhibitory pathogenic C1 domain antibodies are present in patients with hemophilia A and inhibitors. Blood :
Zakas, Philip M; Brown, Harrison C; Knight, Kristopher et al. (2016) Enhancing the pharmaceutical properties of protein drugs by ancestral sequence reconstruction. Nat Biotechnol :
Myers, David R; Qiu, Yongzhi; Fay, Meredith E et al. (2016) Single-platelet nanomechanics measured by high-throughput cytometry. Nat Mater :
Eubanks, Joshua; Baldwin, W Hunter; Markovitz, Rebecca et al. (2016) A subset of high-titer anti-factor VIII A2 domain antibodies is responsive to treatment with factor VIII. Blood 127:2028-34
Chao, B N; Baldwin, W H; Healey, J F et al. (2016) Characterization of a genetically engineered mouse model of hemophilia A with complete deletion of the F8 gene. J Thromb Haemost 14:346-55
Ciciliano, Jordan C; Sakurai, Yumiko; Myers, David R et al. (2015) Resolving the multifaceted mechanisms of the ferric chloride thrombosis model using an interdisciplinary microfluidic approach. Blood 126:817-24
Qiu, Yongzhi; Ciciliano, Jordan; Myers, David R et al. (2015) Platelets and physics: How platelets ""feel"" and respond to their mechanical microenvironment. Blood Rev 29:377-86
Kahle, Joerg; Orlowski, Aleksander; Stichel, Diana et al. (2015) Epitope mapping via selection of anti-FVIII antibody-specific phage-presented peptide ligands that mimic the antibody binding sites. Thromb Haemost 113:396-405
Mannino, Robert G; Myers, David R; Ahn, Byungwook et al. (2015) ""Do-it-yourself in vitro vasculature that recapitulates in vivo geometries for investigating endothelial-blood cell interactions"". Sci Rep 5:12401
Zakas, P M; Vanijcharoenkarn, K; Markovitz, R C et al. (2015) Expanding the ortholog approach for hemophilia treatment complicated by factor VIII inhibitors. J Thromb Haemost 13:72-81

Showing the most recent 10 out of 23 publications